Lorbrexen 100mg Tablet (Lorlatinib)

Lorbrexen 100mg Tablet is a prescription-based anticancer medicine used in the treatment of metastatic ALK-positive non-small cell lung cancer. The active ingredient of the Lorbrexen is Lorlatinib which belongs to the drug class of tyrosine kinase inhibitors. It works by blocking the function of abnormal ALK (anaplastic lymphoma kinase) protein that promote the growth of cancer cells. Lorlatinib Tablet is usually given in combination with another anticancer medicine as a part of combination therapy to increase the efficacy of the treatment.

The tablet must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the Lorlatinib 100mg tablet depend on the patient's condition and response to treatment. It can also be taken with or without food. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include swelling of the arms or legs, weight gain, tiredness, changes in cholesterol or triglyceride levels, joint or muscle pain, diarrhea, constipation, headache, and changes in mood or thinking. A few patients can undergo severe side effects, including neurological or psychiatric effects. Most of the Lorlatinib 100mg tablet side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

Lorlatinib can interact with CYP3A enzymes, therefore review it before the treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Lorlatinib 100mg tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Head and neck cancer, kidney cancer, lung cancer, liver cancer, skin cancer

The human body shows undesired symptoms after taking Lorlatinib 100mg Tablet (Lorbrexen). Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Lorbrexen 100mg Tablet (Lorlatinib) is a prescription-based anticancer drug that should be administered orally. It is advised to take this capsule after consulting your healthcare expert.

This tablet should be swallowed as a whole with water. Don't crush, chew, or break it. It can be taken with or without food. Never skip a dose or double dose.

● Shaw, Alice T., Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres et al. "First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer." New England Journal of Medicine 383, no. 21 (2020): 2018-2029.
● Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., ... & Shaw, A. T. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. The Lancet Oncology, 19(12), 1654-1667.
● Syed, Y. Y. (2019). Lorlatinib: First Global Approval. Drugs, 79(1), 93.
● Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., ... & Shaw, A. T. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. The Lancet Oncology, 19(12), 1654-1667.
● Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., ... & Solomon, B. J. (2020). First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. New England Journal of Medicine, 383(21), 2018-2029.